Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions
Sean M. Fortier, Loka R. Penke, Dana King, Tho X. Pham, Giovanni Ligresti, Marc Peters-Golden
Sean M. Fortier, Loka R. Penke, Dana King, Tho X. Pham, Giovanni Ligresti, Marc Peters-Golden
View: Text | PDF
Research Article Cell biology Pulmonology

Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions

  • Text
  • PDF
Abstract

Myofibroblasts are the major cellular source of collagen, and their accumulation — via differentiation from fibroblasts and resistance to apoptosis — is a hallmark of tissue fibrosis. Clearance of myofibroblasts by dedifferentiation and restoration of apoptosis sensitivity has the potential to reverse fibrosis. Prostaglandin E2 (PGE2) and mitogens such as FGF2 have each been shown to dedifferentiate myofibroblasts, but — to our knowledge — the resultant cellular phenotypes have neither been comprehensively characterized or compared. Here, we show that PGE2 elicited dedifferentiation of human lung myofibroblasts via cAMP/PKA, while FGF2 utilized MEK/ERK. The 2 mediators yielded transitional cells with distinct transcriptomes, with FGF2 promoting but PGE2 inhibiting proliferation and survival. The gene expression pattern in fibroblasts isolated from the lungs of mice undergoing resolution of experimental fibrosis resembled that of myofibroblasts treated with PGE2 in vitro. We conclude that myofibroblast dedifferentiation can proceed via distinct programs exemplified by treatment with PGE2 and FGF2, with dedifferentiation occurring in vivo most closely resembling the former.

Authors

Sean M. Fortier, Loka R. Penke, Dana King, Tho X. Pham, Giovanni Ligresti, Marc Peters-Golden

×

Figure 8

Lung fibroblasts from an in vivo model of fibrosis resolution exhibit similar gene signatures as those determined in myofibroblasts dedifferentiated in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Lung fibroblasts from an in vivo model of fibrosis resolution exhibit si...
(A) Experimental scheme for bleomycin-induced pulmonary fibrosis in Col1α1-GFP+ mice with resolving fibrosis (young) and nonresolving fibrosis (aged); mice were sacrificed on day 30, and fibroblasts were flow sorted from lungs and submitted for RNA-seq. (B) Heatmap display of gene expression in mice with resolving fibrosis (compared with the expression in mice with nonresolving fibrosis). Color scale depicts range of log2 fold changes in gene expression. Tnfrsf10b is the mouse homolog of human TNFRSF10A. Gene expression patterns regulated in parallel (blue) or opposite (yellow) to those exhibited with in vitro treatments of human myofibroblasts are indicated in color-filled boxes to the right of the heatmaps.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts